$IBO News
Last published 1w ago
- 1w agoDSSIBODSS, Inc. Announces SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business CombinationACCESS NewswireSpecial meeting of Impact Biomedical stockholders to approve the proposed Business Combination scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard TimeUpon closing, the combined company is expected to
- 1w agoIBOImpact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business CombinationACCESS NewswireSpecial meeting of Impact Biomedical stockholders to approve the proposed Business Combination scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard TimeUpon closing, the combined company is expected to
- 1mo agoDSSIBODSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar LimitedGlobeNewswireROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS) ("DSS" or the "Company") today announced that Zoar Limited ("Zoar" or "PubCo") has filed a Registration
- 1mo agoIBOImpact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)GlobeNewswireHOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE:IBO) (the "Company" or "Impact") announced that a Form F-4 registration statement (the "Registration Statement") was
- 1mo agoIBOCORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)GlobeNewswireHOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the
- 2mo agoIBOImpact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)GlobeNewswireHOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the "Company") today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's
- 7mo agoIBOImpact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger PlansGlobeNewswireHOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from
- 1y agoIBOImpact Biomedical Inc (IBO) Announces 3F™ US Patent IssueGlobeNewswireHOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled "Composition and Method of
- 1y agoIBODr Ashleys Limited and Impact BioMedical Inc. Announce Strategic MergerGlobeNewswireA Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company ("Dr
- 1y agoIBOImpact Biomedical Inc. Announcement Stock Activity/PricingGlobeNewswireHOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced
- 1y agoIBOImpact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"GlobeNewswireHOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the
- 1y agoDSSIBODSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic GrowthGlobeNewswireROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air purification asset to
- 1y agoIBOImpact BioMedical Inc. to Present at The Microcap ConferenceGlobeNewswireHOUSTON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that
- 1y agoIBOPRPHImpact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic VisionGlobeNewswireHOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that
- 2y agoIBOImpact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory DiseaseGlobeNewswireHOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), is thrilled to announce a significant milestone in its innovative Linebacker™ technology platform. The Canadian Intellectual Property
- 2y agoIBOImpact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and AffiliatesGlobeNewswireHOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, is pleased to
- 2y agoIBOImpact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent IssueGlobeNewswireHOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. ("IBO") is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled "Insect Repelling Composition"
- 2y agoIBOImpact BioMedical Inc. Introduces Leadership Team to Drive Innovation and GrowthGlobeNewswireNEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting unique healthcare solutions, is pleased to
- 2y agoIBOImpact BioMedical Inc. Announces the Closing of its Initial Public OfferingGlobeNewswireNEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the closing of its previously
- 2y agoDSSIBODSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder ValueGlobeNewswireNEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE:IBO), is delighted to announce the successful pricing of Impact BioMedical's
- 2y agoIBOImpact BioMedical Inc. Announces Pricing of Initial Public OfferingGlobeNewswireNEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a company discovering and developing new offerings in human healthcare and wellness today announced the pricing of its initial public